{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:48:06Z","timestamp":1778831286844,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clgc.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:29:26Z","timestamp":1674041366000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT)"],"prefix":"10.1016","volume":"21","author":[{"given":"Fadi","family":"Taza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Abu","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra K.","family":"Althouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Anouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-7414","authenticated-orcid":false,"given":"Reem","family":"Akel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser H.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.01.004_bib0001","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00345-014-1361-y","article-title":"Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009","volume":"33","author":"Nigam","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0002","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group","volume":"15","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0003","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.1993.11.2.324","article-title":"Surgical salvage of chemorefractory germ cell tumors","volume":"11","author":"Murphy","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0004","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2016.69.5395","article-title":"High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University Experience","volume":"35","author":"Adra","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0005","first-page":"386","article-title":"Testicular cancer update","volume":"15","author":"Adra","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0006","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.2002.12.038","article-title":"Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study","volume":"20","author":"Evans","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0007","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00000421-200006000-00010","article-title":"21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature","volume":"23","author":"Saphner","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0008","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2023.01.004_bib0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1200\/JCO.1985.3.11.1471","article-title":"VP-16 and cisplatin as first-line therapy for small-cell lung cancer","volume":"3","author":"Evans","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0011","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.1995.13.5.1167","article-title":"Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors","volume":"13","author":"Cooper","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0012","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1989.7.9.1333","article-title":"A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer","volume":"7","author":"Slevin","year":"1989","journal-title":"J Clin Oncol"},{"issue":"1 Suppl 2","key":"10.1016\/j.clgc.2023.01.004_bib0013","first-page":"36","article-title":"Phase II study of daily oral etoposide in refractory germ cell tumors","volume":"17","author":"Miller","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/annonc\/mdx731","article-title":"Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors","volume":"29","author":"Albany","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0015","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.01.004_bib0016","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0017","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2002.07.158","article-title":"Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group","volume":"20","author":"Hinton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2006.07.7271","article-title":"Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"25","author":"Einhorn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","article-title":"Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"22","author":"Kollmannsberger","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.coc.0000195086.47548.ef","article-title":"Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT","volume":"29","author":"Einhorn","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.01.004_bib0023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10637-009-9280-2","article-title":"Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors","volume":"28","author":"Feldman","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2023.01.004_bib0024","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/COC.0b013e31827de90d","article-title":"Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors","volume":"37","author":"Jain","year":"2014","journal-title":"Am J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732300023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732300023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:42Z","timestamp":1761565062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732300023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S155876732300023X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.01.004","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}